Anadis to sell Travelan in USA
Wednesday, 12 October, 2005
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories.
Anadis is currently in discussions with prospective US partners to begin sales of Travelan.
Travelan is based on antibodies from bovine colostrum, the 'first milk' of dairy cows which have been specifically immunised with antigens from pathogenic human bacteria and viruses, such as strains of E. coli bacteria that cause traveller's diarrhoea.
Travelan contains antibodies to 14 pathogenic strains of E. coli bacteria found in water supplies around the world.
The company is also seeking registration for Travelan in Canada, Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, the United Kingdom and Europe.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
